Orphan Drugs Need Separate Category In Medicare Formularies, BIO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The Biotechnology Industry Organization is advocating the creation of a separate category for orphan drugs within Medicare drug plan formularies
You may also be interested in...
USP Draft Medicare Formulary Sets 146 Drug Categories And Classes
The proposed total is greater than the number of classes desired by PBMs but falls below the threshold drug manufacturers are seeking. Medicare Part D plans following the model formulary would have to offer at least two drugs in each therapeutic category and pharmacologic class.
Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability
McKindler? New Pfizer CEO Echoes McKinnell’s Views On Payers, Scale
Pfizer's success will depend on its ability to negotiate the paradox of increasing demand for pharmaceuticals coupled with growing attempts to restrain costs, CEO Jeffrey Kindler said